Clinical trial · Interventional
Iodine I 131 in Treating Patients With Thyroid Cancer
Dose-Response in Radionuclide Therapy of Thyroid Cancer
NCT00416949CI-TRIAL-00033845terminatedN/AResults postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Study was terminated due to loss of funding.
Summary
Brief summary (as posted)
RATIONALE: Radioactive iodine kills thyroid cancer cells by giving off radiation. PURPOSE: This clinical trial is studying the side effects, best dose, and how well iodine I 131 works in treating patients with thyroid cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Head and Neck Cancer | Malignant Head and Neck Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Patient-specific dosimetry | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Patient-specific 3D-RD Dosimetry
- description
- Applied a patient-specific dosimetry calculation method to the imaging data collected to calculate tumor absorbed doses, using 3D-RD method.
- interventionNames
- Device: Patient-specific dosimetry
Primary outcomes (1)
- measure
- Tumor Absorbed Dose
- timeFrame
- up to 4 years
- description
- Tumor absorbed doses (Gy) calculated using patient-specific dosimetry.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 100 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Diagnosis of thyroid cancer * Measurable disease by CT scan or nuclear medicine imaging * Eligible, by standard of care criteria, for iodine I 131 therapy PATIENT CHARACTERISTICS: * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective non-barrier method contraception (e.g., combined or progesterone-only oral contraceptive pill, intrauterine device, depot progesterone, or stable relationship with a partner who has had a vasectomy) * No other malignancy within the past 5 years except squamous cell or basal cell carcinoma of the skin * No nonthyroidal conditions known to affect iodine I 131 uptake (e.g., New York Heart Association class III or IV congestive heart failure or renal failure) * No alcoholism or drug abuse within the past 2 years * No severe emotional, behavioral, or psychiatric problems that would preclude study compliance (e.g., severe claustrophobia) PRIOR CONCURRENT THERAPY: * No intravenous water-soluble radiographic contrast within the past 4 weeks * No iodinated contrast agent within the past 3 months * No concurrent drugs that may affect thyroid or renal function (e.g., renal drugs, lithium, amiodarone, other iodine-containing medication, or corticosteroids) * No other concurrent investigational drugs
References
Publications (0)
Data not yet available
No reference posted for this study.